Small Molecule Inhibitors of the Trimeric Influenza Virus Polymerase

FLUINHIBIT aims at discovering small molecule inhibitors of the influenza virus A subunit interaction between PA and PB1, crucial for viral replication.Starting from an inhibitory peptide, and supported by characterization of the PB1-binding domain of PA, molecular modeling will be employed to rationally design and synthesize peptidomimetics via traditional medicinal chemistry and a novel fragment based library synthesis approach. In parallel, a high-throughput assay will be developed to screen large compound collections and unique in-house small molecule libraries. The resulting hits will be profiled in cell-based assays and lead candidates with antiviral activity will be identified for preclinical development.


Biotechnology companies

PiKe Pharma GmbH, Switzerland

Inte:Ligand GmbH, Austria

Academic institutions

University Hospital Freiburg, Freiburg, Germany

Institute of Biotechnology, Vilnius, Lithuania

Helmholtz Centre for Infection Research, Braunschweig, Germany

University of Siena, Siena, Italy


Ronald Frank


PiKe Pharma GmbH (CH)



Funding Agency